Welcome to CRWENewswire, Stocks to Watch. I am Shalika Jayasekera. Ventrus BioSciences Incorporated – symbol VTUS – reported that it has completed its acquisition of all rights and title to VEN 309 – iferanserin ointment for the treatment of symptomatic hemorrhoids – from the licensor, Sam Amer & Company. Based on a report by the National Institute of Diabetes and Digestive Kidney Diseases, the company estimates that symptomatic hemorrhoids currently affect approximately 12.5 million adults. Ventrus is a development stage specialty pharmaceutical company focused on the development of late-stage prescription drugs for gastrointestinal disorders. Thanks for joining me and have a great day! For CRWE Newswire, Stocks to watch, I’m Shalika Jayasekera

Leave a Reply

Your email address will not be published. Required fields are marked *